Glutamate Antagonists for Parkinson's Disease: Rationale for Use and Therapeutic Implications

Author： Cooper A.J.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.9, Iss.6, 1998-06, pp. : 421-429

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.  

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

By Kaakkola S.  

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure

By Rocha R.  

Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. : 723-731

Adis International

Access to resources Recommend Favorite

Tolcapone-Related Liver Dysfunction: Implications for Use in Parkinson's Disease Therapy

By Borges N.  

Drug Safety, Vol. 26, Iss. 11, 2003-01 ,pp. : 743-747

Adis International

Access to resources Recommend Favorite

Gene Therapy in Parkinson's Disease: Rationale and Current Status

By >   Maguire-Zeiss Kathleen A.  

CNS Drugs, Vol. 24, Iss. 3, 2010-03 ,pp. : 177-192

Adis International

Access to resources Recommend Favorite